25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial

2021 ◽  
Vol 85 (3) ◽  
pp. AB70
Author(s):  
Kristian Reich ◽  
Joseph F. Merola ◽  
Boni Elewski ◽  
Kim A. Papp ◽  
Luis Puig ◽  
...  
Keyword(s):  
Severe Psoriasis ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials

2021 ◽  
Author(s):  
Mark G. Lebwohl ◽  
Ahmed M. Soliman ◽  
Hongbo Yang ◽  
Jessie Wang ◽  
Kaitlin Hagan ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Severe Psoriasis ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies

2021 ◽  
Author(s):  
Timo Buhl ◽  
David Rosmarin ◽  
Esther Serra-Baldrich ◽  
Pablo Fernandez-Peñas ◽  
Atsuyuki Igarashi ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals What Does it Mean to be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials

2021 ◽  
Author(s):  
Richard Furie ◽  
Eric F. Morand ◽  
Ian N Bruce ◽  
David Isenberg ◽  
Ronald van Vollenhoven ◽  
...  
Keyword(s):  
British Isles ◽  
Phase 3 ◽  
Post Hoc Analysis ◽  
Post Hoc
Sign in / Sign up

Export Citation Format

Share Document